Skip to main content
PLOS ONE logoLink to PLOS ONE
. 2021 Mar 11;16(3):e0247328. doi: 10.1371/journal.pone.0247328

Barriers and facilitators to use of a mobile HIV care model to re-engage and retain out-of-care people living with HIV in Atlanta, Georgia

Michelle E Henkhaus 1, Sophia A Hussen 1,2, Devon N Brown 1, Carlos del Rio 1,2, Michelle R Fletcher 1, Marxavian D Jones 1, Amulya Marellapudi 1, Ameeta S Kalokhe 1,2,*
Editor: Bronwyn Myers3
PMCID: PMC7951832  PMID: 33705421

Abstract

Novel strategies to re-engage and retain people living with HIV (PLWH) who are out of care are greatly needed. While mobile clinics have been used effectively for HIV testing and linkage, evidence guiding their use in providing HIV care domestically has been limited. To guide the development of a mobile HIV clinic (MHC) model as a strategy to re-engage and retain PLWH who are out of care, we aimed to explore stakeholder perceptions of barriers and facilitators to MHC implementation and use. From June 2019-July 2020, we conducted 41 in-depth interviews with HIV clinic providers, administrators, staff, legal authorities, and community advisory board members, PLWH, AIDS service organizations and city officials in Atlanta, Georgia, and domestic and international mobile health clinics to explore barriers and facilitators to use of MHCs. Interviews were transcribed, coded and thematically analysed. Barriers raised include potential for: breach of confidentiality with resulting heightened stigmatization, fractured continuity of care, safety concerns, staffing challenges, and low community acceptance of MHC presence in their locality. Participants provided suggestions regarding appropriate exterior design, location, timing, and co-delivery of non-HIV services that could facilitate MHC acceptance and address the concerns. In identifying key barriers and facilitators to MHC use, this study informs design and implementation of an MHC as a novel strategy for re-engaging and retaining PLWH who are out of care.

Introduction

Despite widespread availability of potent antiretroviral therapy (ART), less than half the 1.1 million people living with HIV (PLWH) in the United States (US) are virally suppressed [1]. Engaging and retaining patients in HIV care is critical for ART adherence and viral suppression [2], but is limited by several barriers including un-/underinsurance, lack of transportation, housing insecurity, mental health and substance abuse comorbidities, poor social support, inaccessibility of healthcare, social norms, and poverty [3]. In the Southern US, medical mistrust [4] and pervasive stigmas (e.g., around HIV [5], minority sexual orientation, poverty, substance abuse, and mental disorders [6]) pose additional retention challenges [7]. Evidence-based retention interventions address many of these barriers and include: provision of social support services, case management [8], child care, housing services, appointment reminders, co-location of services, appointment accompaniment [9], patient navigators [10], peer support [11], educational brochures [12], outreach, and transportation assistance [8, 9, 1316]. While each of these interventions has demonstrated promise, continued shortcomings in achieving national retention goals suggest the need for new re-engagement and retention strategies tailored to the needs of PLWH who have fallen out of care [17, 18].

Some experts have proposed the use of mobile health clinics to facilitate access to HIV care for difficult-to-reach populations [19]. Mobile health clinics typically deliver health care on a van or bus that can move to different locations and thus provide medical services directly in multiple communities rather than in a traditional, static clinic-based setting. Mobile health clinics have been used for a range of medical purposes (e.g., asthma care, maternal and infant health services) [20, 21]. Within the field of HIV, their use has been largely limited to HIV testing and counselling services [2227]. Less commonly, mobile health clinics have been used for the provision of HIV care. In sub-Saharan Africa, mobile health clinics are being used to expand HIV services to rural areas in Mozambique [28], Swaziland [29], Kenya [30], South Africa and Uganda [31]. Mobile health clinics are much less common in US-based HIV care, but have been used in the context of needle exchange programs [32] and as part of broader primary care services for people who are homeless [3335].

Evidence from other settings suggests that mobile health clinics are highly acceptable and have several advantages over traditional clinics [25, 26, 36] including their potential to address transportation barriers, to foster patient-centered care, and to lessen intimidation of patients by traditional healthcare settings [20, 37]. However, there are potential challenges to their use in provision of US-based HIV care that need to be explored prior to implementation. We sought to comprehensively explore key stakeholder perspectives on the barriers and facilitators to the use of mobile HIV clinics (MHCs) as a means of reengaging and retaining PLWH who have fallen out of care in Atlanta, Georgia.

Methods

Overview

This qualitative sub-study is nested within a larger mixed-methods pre-implementation study that aims to prepare for utilization of an MHC to re-engage and retain PLWH who are out of care. To explore perceived barriers and facilitators of MHC use, we conducted in-depth interviews with key stakeholders of a large Ryan White-funded infectious diseases clinic, surrounding agencies that provide HIV support services in Atlanta, Georgia, and existing MHCs from June 2019 through July 2020. The study was approved by the Emory University institutional review board and the Grady Research Oversight Committee. Written informed consent was obtained from each subject prior to participation for in-person interviews and oral consent was obtained for interviews conducted by videoconference.

Participants

Potential participants were purposively sampled to explore a diversity of perspectives about the MHC. Sampling targets included 10 clinic staff and providers, 10 PLWH (5 out-of-care PLWH and 5 PLWH who were clinic Consumer Advisory Board [CAB] members), 10 staff from organizations providing community-based HIV clinical and support services, and 10 institutional and city-based regulatory, billing, and, medico-legal compliance experts [38]. Organizations providing community-based HIV care and support included AIDS Service Organizations (ASOs) working with different groups of PLWH (i.e. gay/bisexual men, women, transgender women, under- and uninsured patients) and mobile clinics providing HIV-related care domestically and internationally. The clinic CAB is an existing group of approximately 10 PLWH who receive HIV care at the study clinic. They were nominated to the CAB based on their interest in HIV advocacy and in enhancing the services provided within the clinic’s Ryan White Program. They represent various racial/ethnic, gender and sexual minority groups, and many endorse having had a period in their lives where they were out-of-care or struggled with their HIV diagnosis and appointment adherence and are able to describe strategies they used to overcome the challenges. PLWH who were out of care (i.e. not seen by an HIV care provider in the preceding 6 months) were recruited through the clinic’s list of out-of-care patients and from hospital settings. The remainder of participants were recruited through email, direct contact, and the clinic newsletter. Enrollment concluded once the research team determined theoretical saturation was reached.

Study procedures

Study protocols and interview guides were reviewed by the CAB and revised based on feedback. Interviews were conducted at the clinic or at a mutually convenient off-site private location (i.e. public library, workplace, inpatient hospital room), or by phone or Zoom video conference when participants were unable to meet in person. All interviews were audio-recorded and followed a semi-structured interview guide. Interview guides were tailored to each stakeholder group, and while each guide included open-ended questions about perceived facilitators, barriers, and strategies for using an MHC to deliver HIV care to PLWH who had fallen out of care, probes that followed were tailored to the unique expertise of each stakeholder group. For example, in follow-up to an open-ended question about perceived challenges with mobile HIV care delivery, providers and staff were probed about time, support, and technology challenges, while patients were probed about accessibility and location challenges. New insights from the interviews were shared at weekly research staff meetings and then probed by interviewers in subsequent interviews. The average interview duration was 47 minutes. Participants were compensated $50 for completing the interview.

Analysis and data management

All interviews were transcribed verbatim. Transcripts were reviewed for quality and de-identified. We commenced coding alongside conducting the interviews, so that inductive codes arising from earlier transcripts could be probed further in subsequent interviews. The codebook was developed after the first three interviews and included deductive codes derived directly from the interview guide and inductive codes that emerged directly from the interviews. To establish consistency of coding and interpretation, definitions and examples of each code were included in the codebook and discussed at research team meetings, all transcripts were coded by two research team members using MAXQDA Plus 20.0.4, and discrepancies in coding were discussed until consensus was reached. When consensus could not easily be reached between the two coders regarding interpretation of a transcript and appropriate code, the code and text in question was presented at the weekly team meeting for further discussion until consensus was achieved. Thematic analysis on coded interviews was applied to examine barriers and facilitators to use of the MHC model.

Results

Participant characteristics

We conducted 41 interviews (Table 1) with PLWH who were out-of-care (n = 5), Ryan White clinic providers, administrators, and staff (n = 14), ASO staff members (n = 7), CAB members (n = 6), mobile health clinic staff (n = 5), and institutional and city legal and regulatory officials (n = 4). Participants described potential barriers to use of an MHC, that if not addressed would decrease the effectiveness of the model, and also facilitators to enhance the effectiveness of the model and address the identified barriers. Potential barriers and facilitators were organized thematically into patient-level, clinic-level, and environment-level barriers.

Table 1. Participant characteristics.

Participant Category Number Roles
People Living With HIV who were out-of-care 5 --
Ryan White clinic providers/staff/administrators 14 Physician, Nursing staff, Mental Health staff, Social Worker, Peer Navigator, Administrator
AIDS-service organization staff 7 HIV care, HIV prevention and awareness, primary care inclusive of HIV care
Ryan White clinic community advisory board members 6 --
Mobile health clinic staff 5 County health department, syringe exchange, HIV testing
Institutional and city legal and regulatory officials 4 Compliance officer, Ryan White program manager, city attorney
Total 41

Patient-level barriers and related facilitators

Potential patient-level barriers to an effective MHC model include: concerns around confidentiality and stigma, physical and emotional comfort, patient hesitancy to trust a new clinic with possible new providers, accessibility, the possibility of patients being more likely to fall out of other necessary medical care, and potential for decreased patient responsibility and self-efficacy in care. Facilitators are described in relation to the respective barriers below.

Confidentiality and stigma concerns

Given the persistent stigma associated with HIV, the potential for MHCs to breach patient confidentiality (i.e. through the outside appearance of the van, location, and services provided identifying patients as living with HIV) was a concern brought up by almost every participant, and across stakeholder groups.

I’d say the challenges and barriers are the stigma of being seen. If, you know, it is—if people recognize this mobile unit as an HIV treatment unit in the community, and then if a member of the community gets on to this mobile unit, people are automatically going to know possibly what this person’s HIV status is.

-Mobile health clinic staff

I mean I feel like it’s just more open. Like it’s more out there…like what, what if somebody who—who wants to know information about why that’s there in the community… I mean I could see it working for certain communities but umm I think it would be very convenient in certain, but for me because my family still doesn’t know and community and other people I know doesn’t know—don’t know, so it would be kind of like I wouldn’t do it.

-PLWH

Other patients discussed that potential breach of confidentiality was a tolerable risk if it meant receiving accessible care:

Well, I’m comfortable regardless because I know this clinic is something to help me, so I wouldn’t be uncomfortable at all. That would be fine… because I know that once you go into the clinic, he [the HIV care provider] has to close the door so it’s privacy there just between me and him. So the person outside they can’t hear what’s going on, so I wouldn’t feel unsafe.

-PLWH

Participants across all stakeholder groups also described numerous facilitators of patient confidentiality and privacy including incorporation of strategies that diminish chance of disclosure of the true intent of the van (i.e. through nesting HIV care among other services), that detract attention from the MHC in the community, and that limit the likelihood of patients coming across one another on the vehicle.

If you could do like just a general medical bus, where they can get HIV care but also maybe they’re doing free checks or health checks, blood pressure checks, you know, um so you’re …pulling other people in.

-PLWH

I think if it’s in a generic area that blends in. Not on the street, but like a strip mall but over to the side where people are not, it’s not where you’d just see it. It kind of blends in with what’s going on in that neighborhood… You know what I mean? People are moving.

-Social Worker

Lack of physical and emotional comfort

Participants also raised concerns regarding patients’ physical and emotional comfort, specifically, whether patients would feel welcome, whether they would feel comfortable in the waiting area, and comfortable with the MHC location. These concerns were expressed primarily by PLWH, CAB members, providers and staff in the clinic, and those that worked at ASOs and on mobile health clinics. Facilitators were described by all stakeholders, and included a welcoming outside vehicle appearance, comfortable waiting area with amenities (i.e. water, snacks, air conditioning, and phone chargers), culturally-competent and caring staff with diversity reflective of the community served, and a frequent MHC presence in the community.

Spruce it up with some warm colors and comfortable seats, and …it feels better than a waiting room… Some people hate hospitals. And just making the care more comfortable, more approachable, less health care-ish.

-ASO staff member

Maybe partner with [a community-based organization that provides meals] and then when they leave out of the clinic then they get a sandwich and something to drink…That’ll encourage and make them want to come because at least they know when they get there when they leave the doctor they got a sandwich, a dessert, a snack and something to drink, you know.

-PLWH

You know what, have a greeter, have somebody at the door, “Hi, welcome,” and stuff. Don’t just have us come in and then they sit there and then you say, “yes ma’am.” No, greet, “Hi, how are you doing today?” That makes you feel so much more comfortable. It’s just the tone of the place, you know that I mean? It’s a happy place.

-PLWH

Responding to how one can make an MHC the most effective, acceptable, and safe place as possible, a mobile health clinic staff member described creating familiarity and comfort:

We collaborate with other community-based organizations in the area, so maybe you [the patient] may not be familiar with [our clinic], but you’re familiar with another organization that we’re collaborating with at the time. Make it more comfortable, and I feel like, you know, more frequent presence in the community, you know, become more familiarized with us. So, that kind of stigma, you know, the stigma is reduced.

-Mobile health clinic staff

Hesitancy to trust a new clinic and new providers

Participants, primarily clinic providers and staff and ASO staff members, expressed that patients might be hesitant to trust an MHC model because of the unfamiliarity with receiving HIV care in a mobile setting, possible past negative experiences with HIV testing vans, and potentially new and unfamiliar service providers operating the van.

Maybe just because it’s new, right? Just getting people to say, oh, wait, we are doing this in a van? Like, what are we doing? Because the last time somebody pulled up in a van, they were giving me $25 for a survey, right? So just trusting, like, hey, we actually work for [healthcare institution]…You can actually have a real appointment here if you want to, right?

-Social Worker

Cons would be, who are these people? Uh does it feel like I’m receiving care from a stranger?

-ASO staff member

However, participants also expressed that trust in the MHC model would be facilitated by communicating the model through providers and peer navigators, word of mouth, patient trust in the larger healthcare institution, provision of quality care, and time itself.

But I think also [healthcare institution] is a trusted brand. I mean, everyone knows the logo, everyone knows the name. It’s Atlanta. Like, you’re trusted to be like a powerful entity in the city of Atlanta with regards to healthcare that’s able to do things maybe other places aren’t… [healthcare institution] is a trusted name in healthcare, but also HIV care.

-ASO staff member

I think patients once they see what it can offer, will really put the word out ourselves. So if we make it the best that it can possibly be and really put our best foot forward then our patients will be our best our advocates for it and keep it going.

-Nursing staff

Accessibility concerns

The convenience and accessibility of the van, including location and parking availability, were raised as key factors by clinic staff and providers, ASO staff members, CAB members, and PLWH, impacting the effectiveness of the MHC model.

How are you going to target specific areas if, because Atlanta is so spread out, and I think our population is also kind of spread out. And though there might be some hotspots across Atlanta, I guess, how to be able to reach everyone that might need.

-ASO staff member

We have to find a good, convenient spot that all they got to [do] is if they drive or jump off the bus then they’re right there… They ain’t gonna come if it’s a long ways to walk, you see what I’m saying?

-PLWH

Decreasing patients’ responsibility and self-efficacy in their care

Bringing HIV care and services to patients might have the unintended effect of reducing patient responsibility and self-efficacy in care, a concern expressed primarily by clinic providers and staff.

Yeah I think it might create this sense for patients um that…that the provider is sort of always available to them. It might make them less inclined to um…be active in their care… The unwitting message that might be sent to the patient is ‘you are incapable of coming in right so, so you’re fragile so we need to um, we need to make sure you don’t leave and that we sort of attend to you in this way.

-Mental health clinician

A second participant expressed concern that patients would fall out of other necessary, less convenient medical care,

Many patients that we see have sort of multiple medical needs, so you know if they sort of need to sort of see a specialist would they be less inclined to then go someplace else to get their [other treatments]?

-Mental health clinician

Some participants suggested that this barrier could be addressed if the MHC could be used successfully as a gateway to re-engagement in long-term care at a traditional fixed clinic.

Yeah, we’re gonna be with you for a while, we’re gonna get you up on on your feet and then, you need to come to [the regular clinic].

-Healthcare provider

Clinic-level barriers and related facilitators

Clinic-level barriers include: potential high cost, limited capacity, safety concerns, staffing and time limitations, ability to handle emergencies, adequate awareness of the MHC among the target population, ability to provide HIV care of equal quality to that of traditional clinic-based models, fragmentation of existing patient-provider relationships, and discontinuity of care. Facilitators to address clinic-level barriers are described in relation to the respective barrier.

Potential high cost

Some participants, primarily clinic staff and providers, institutional regulatory officials, and ASO staff members, expressed concern over MHC cost-effectiveness, specifically voicing high start-up costs, variable usage, capacity to treat only a few patients at a time, and that it could be a bad steward of providers’ time and clinic money in having substantive resources devoted to a few hard-to-reach patients.

Are we looking for ten people to be on the mobile clinic and we only have five today? Is that still a successful thing? So, we have to have that conversation…What is the cost benefit factor?

-Compliance official

Other participants, primarily including clinic providers, mobile health clinic staff, and ASO staff, thought it would be cost-effective:

I mean honestly, it seems cheaper, more cost effective than having a brick and mortar.

-ASO staff member

They discussed that scheduled appointments rather than walk-in visits could reduce associated costs.

There could be days where you have no one and it’s not a very good um steward of time or money…But I think it can be overcome with a schedule.

-Nursing staff

Limited capacity

Some, primarily ASO staff members and clinic staff and providers, raised concerns about the limited capacity of an MHC model due to space constraints limiting the number of providers, services provided, and number of patients seen at a given time.

How can you get all of the health care team, all the essential pieces into a little van? I don’t know if there would be a model, and this might be thinking way too far outside the box, but having a model instead of just a van, but doing a trailer, dropping off a trailer for, say, a month, and then having more space for these services, and then the next month being in another location and only kind of serving two to three miles radius every month.

-ASO staff member

To address the limited physical capacity of MHCs, participants suggested limiting HIV and non-HIV services to those most critical, integrating with other delivery models like telemedicine, and ensuring strong systems of referral and integration into the larger health care system.

Safety concerns

Participants, primarily clinic staff and providers, institutional regulatory officials, ASO staff members, and CAB members, expressed concern for the safety of providers, patients, and supplies, voicing that the MHC could be a target for theft of equipment, medications, and prescription pads, and stigma-related violence if associated with HIV care. Safety concerns were affected by the locations the van operated in as well as community acceptance.

What would you do about security? Um, there’s you know, there’s, there’s a lot of um hateful people and you know, so you know those are some concerns I have. Um, you know I, I, I’d hate for a mobile clinic—I’d hate for any clinic to be a target of uh of you know any kind of violence or hatred.

-CAB member

To facilitate safety, participants, especially mobile health clinic staff and clinic staff and providers, suggested working with police to determine appropriate locations and area exit plans, notifying police of the schedule, providing staff and providers with safety training, adding security personnel or utilizing the driver as security personnel, limiting the medications on the vehicle, and installing a lockbox, panic button, camera, and signs to facilitate safety.

The safety thing, it’s just a matter of access. Other than people having the misperception that it contains something that it doesn’t but that’s easily fixed by just saying, … “no more than [a certain amount of cash] is on hand anytime” disclaimer out there. There’s nothing on here, maybe a computer but yeah, just making its known. No medications, no narcotics, nothing of that nature is here.

-Nursing staff

Staffing and time limitations

Participants, primarily clinic staff and providers and institutional regulatory officials, expressed concern with the MHC being staffed by existing clinic staff and providers, who were already being utilized at full capacity. Some, including staff of existing mobile health clinics, suggested staffing the MHC with advanced practice providers to preserve physicians’ limited time.

With my schedule, I can’t just go on a mobile clinic… would it be like in place of a half-day of clinic, I’d go on the mobile van? Or, am I going to be asked to do it in addition to my clinic slots, which would be very difficult for me to do personally.

-Healthcare provider

Ability to handle urgent and emergency situations

To facilitate handling of urgent and emergent situations, participants, primarily clinic staff and providers and institutional regulatory officials, stressed that the MHC model should include appropriate protocols, equipment, and adequate number of personnel.

It’s like alright, um… somebody falls on the floor, they’re half dead, who’s gonna help the doctor?

-Nursing staff

They further discussed a need for the MHC to integrate with the health care system to maintain continuity of care during urgent medical situations.

Adequate awareness of the MHC among the target population

Participants across all stakeholder groups raised concerns of inadequate awareness of the MHC among the target population leading to underutilization. They also expressed concern of being able to “market” and communicate about the model to PLWH without targeting patients or exposing it as an HIV-specific van.

There’s going to have to be a great deal of effort on the part of the clinic staff to make patients aware and to truly make them aware … In my mind I just honestly believe that people should just drive and literally go and locate where people say they are living.

-Nursing staff

Participants noted ways to facilitate awareness: through communication about the MHC option to patients in the fixed clinic before the patients fall out of care (i.e. during clinic orientation), through peer navigators that go into the community to reach patients who have fallen out of care, through flyers in the fixed clinic, through social media, and through word of mouth and visual reminders resulting from the MHC being seen in the community.

Reach people through social media, especially with our current population, so… we let the public know where we will be on the mobile unit and when we’ll be there.

-Mobile health clinic staff

Potential lack of HIV care provision of equal quality to the clinic setting

Some, including ASO staff members and clinic providers and staff, expressed concern about whether the MHC could provide care of similar quality to a fixed HIV clinic. While some participants voiced that all services provided at the fixed clinic should be available in an MHC model, others discussed that patients should not expect the MHC to provide the same level of care but rather, be used as a re-engagement tool with linkage and integration into the health care system.

The care should be measurable, comparable [to the clinic]. They should be the same, you know what I mean? I, I shouldn’t be like, Dang, this? I gotta go in this van, it’s broken down, you know? Or I could go to a, the clinic and it’s you know. It should, it should be the same. It should be the same look, feel.

-Social Worker

There’s a stigma about being poor, and like getting crappy resources for everything…the way public health often looks is like look, we’re not going to give you anything, except we’re going to control this epidemic, right?… The danger to me is like, do we further alienate people and you know, when we don’t integrate things into a larger care model, like is it worth it? Like does it maybe have more long-term risks in our ability to like talk about HIV more productively?

-ASO staff member

Fragmentation of existing patient-provider relationships and discontinuity of care

While clinic providers and staff and institutional regulatory officials raised potential fragmentation of existing patient-provider relationships, especially if a patient’s primary HIV physician was not on the MHC van, as a concern, they voiced this could be overcome by integration of the MHC into the wider healthcare system.

I love my patients and I love my relationships with them and I don’t want to lose it because of, because of this… I would want the goal of the HIV um mobile clinic, that that goal is to get you back to me.

-Healthcare provider

Environmental-level barriers and related facilitators

At the environmental level, barriers to an effective MHC model include community acceptance and safety. Facilitators to community acceptance and safety are also described here.

Community acceptance and safety

Participants across all stakeholder groups except PLWH discussed that the success of the MHC van depended on community acceptance. Negative community perceptions of the MHC van could spur stigmatizing action towards patients, make the van a target for violence or hatred, and inadvertently deter patients from utilizing the services. Participants described that community acceptance could be facilitated by partnering with organizations who are trusted by the community, seeking support from local government, seeking and addressing community concerns before implementation, and embedding HIV care within other health services of benefit to the community’s wellness.

If you get a neighborhood up in arms, they’re going to come in and meet with their council member and the next thing you know, there’s legislation coming out that regulates you.

-City Official

Just reaching out ahead of—before the fact—to the local governments, to the city and the other local governments and finding out you know, developing, establishing the relationships…developing partnerships with existing—with existing agencies, is probably a good way to do that, or a good way to get the support of the local governments.

-City Official

Discussion

By “bringing the clinic to the community,” MHCs have potential to revolutionize HIV care for out-of-care PLWH in the U.S. This exploratory study lays critical groundwork for the design of MHC models through examining key stakeholder perceptions about barriers and facilitators to MHC acceptance and use. Factors identified as critical to successful MHC uptake include: 1) adequacy of strategies to reach and engage PLWH who are out of care, 2) patient sense of physical and emotional comfort inclusive of confidentiality and privacy, 3) breadth of HIV and non-HIV services offered, 4) understanding of the community context in which the MHC is to be implemented, and 5) implementation costs inclusive of opportunity costs (Fig 1).

Fig 1. Key considerations to implementation of a mobile HIV care model to reach people living with HIV who are out of care.

Fig 1

Common strategies used by other mobile clinics to raise awareness of services among target populations (i.e. vehicle signage, community postings, and television and radio advertising in targeted areas) [27], are not feasible for MHC models given HIV-associated stigma. Instead, the present study and others have highlighted the need for appointments to be scheduled and patients to be notified of the appointments through pagers [39], phone call reminders, or home visits by peer educators. Additionally, MHCs should be located in easily accessible areas (i.e. near communities of patient residence, along public transportation routes) to foster awareness and accessibility. Limited literature guides methods for increasing patient sense of physical and emotional comfort with mobile clinics. Our study affirms strategies used by MHCs in other settings to preserve privacy and confidentiality (i.e. nesting HIV care within other health services, using non-descript MHC labelling), and underscores the importance of establishing safety and emergency response protocols. Study participants suggested equipping the MHC with security personnel, however this needs to be weighed against potential for patient re-traumatization given high baseline rates of incarceration in this patient population. To foster trust, our study emphasized the need to communicate about the MHC model through HIV care providers and peer navigators and to ensure care was provided in a culturally-sensitive manner and of quality equivalent to that provided in the fixed HIV clinic. Ensuring a breadth of HIV and non-HIV services to incentivize utilization, provide comprehensive care, safeguard confidentiality, and mitigate stigma are strategies used by other MHCs and syringe exchange programs [32, 33, 35]. To overcome concerns around limited MHC capacity, care fragmentation, and diminished patient self-efficacy in care and access of other necessary medical care, care provided on the MHC should be integrated into the larger healthcare system (i.e. through strong closed-loop referral systems, incorporation of telemedicine), and could potentially be used as a transitionary model for patients to ultimately return to the fixed HIV clinic.

Understanding of community context (i.e. safe spaces, parking availability, local regulations, existence of trusted community-based organizations with whom the MHC could partner) was deemed in our study as key to community MHC acceptance, and has been accomplished by others through including community members in the planning [40]. Lastly, other studies of mobile clinics have echoed high start-up and maintenance costs, but deemed them a worthwhile long-term investment [27]. Strategies to increase cost-effectiveness include scheduling appointments, offering services beyond HIV, and using the MHC as a transitionary model to long-term clinic-based HIV care.

The study strengths include its exploration of a new model of HIV care to reach out-of-care PLWH, its examination of a wide breadth of stakeholder perspectives to understand factors affecting MHC adoption, CAB involvement in study conceptualization, and transcript coding by two study team members. Study limitations include recruitment from a single clinic which may affect transferability of findings to other clinics, and the use of a broad definition for “out-of-care” PLWH. The definition unintentionally resulted in inclusion of some patients whose medical appointments were purposefully spaced to greater than 6 months as a result of the patients achieving longstanding viral suppression; thus, some perspectives may not have been reflective of patients who are truly “out-of-care.”

In conclusion, this study lays the foundation for the development of a stakeholder-driven MHC to re-engage and retain PLWH. Key factors influencing use of the MHC include the extent to which patients feel physically and emotionally safe (including their perceptions of the potential of the MHC to maintain confidentiality and privacy), the extent to which the MHC provides comprehensive integrated HIV and non-HIV services, the level of community acceptance of the MHC, cost-effectiveness of the model, and the development and use of effective strategies to reach and engage out-of-care PLWH. Next steps include development of the MHC model to address these factors with the continued participation of the various stakeholders, followed by MHC piloting. Future studies will evaluate the effectiveness of the resulting MHC in enhancing retention and viral suppression relative to traditional fixed-clinic HIV care.

Acknowledgments

We would like to acknowledge the Emory CFAR Prevention Science Core for provision of data collection devices. We express utmost gratitude toward each of the individuals who participated in the study and openly shared their perspectives with us.

Data Availability

The data underlying this study cannot be shared publicly because of confidentiality concerns. Data are available from the Emory IRB (irb@emory.edu) or via the corresponding author.

Funding Statement

This study was funded by the National Institutes of Health/National Institute of Allergy and Infectious Diseases through the Emory Center For AIDS Research (P30 AI050409) to ASK. http://www.cfar.emory.edu/; https://www.niaid.nih.gov/; The funders had no role in the study design, data collection, and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.HIV Continuum of Care, U.S., 2014, Overall and by Age, Race/Ethnicity, Transmission Route and Sex2017. https://www.cdc.gov/nchhstp/newsroom/2017/HIV-Continuum-of-Care.html.
  • 2.Department of Health and Human Services. National HIV/AIDS Strategy for the United States: 2017 Progress Report.
  • 3.Mugavero MJ, Amico KR, Horn T, Thompson MA. The State of Engagement in HIV Care in the United States: From Cascade to Continuum to Control. Clinical Infectious Diseases. 2013;57(8):1164–71. 10.1093/cid/cit420 [DOI] [PubMed] [Google Scholar]
  • 4.Kalichman SC, Eaton L, Kalichman MO, Grebler T, Merely C, Welles B. Race-based medical mistrust, medication beliefs and HIV treatment adherence: test of a mediation model in people living with HIV/AIDS. Journal of Behavioral Medicine. 2016;39(6):1056–64. 10.1007/s10865-016-9767-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Reif S, Safley D, McAllaster C, Wilson E, Whetten K. State of HIV in the US Deep South. Journal of Community Health. 2017;42(5):844–53. 10.1007/s10900-017-0325-8 [DOI] [PubMed] [Google Scholar]
  • 6.Costelloe S, Kemppainen J, Brion J, MacKain S, Reid P, Frampton A, et al. Impact of anxiety and depressive symptoms on perceptions of stigma in persons living with HIV disease in rural versus urban North Carolina. AIDS Care. 2015;27(12):1425–8. 10.1080/09540121.2015.1114993 [DOI] [PubMed] [Google Scholar]
  • 7.Centers for Disease Control and Prevention. HIV in the Southern United States. 2019.
  • 8.Andersen M, Hockman E, Smereck G, Tinsley J, Milfort D, Wilcox R, et al. Retaining Women in HIV Medical Care. Journal of the Association of Nurses in AIDS Care. 2007;18(3):33–41. 10.1016/j.jana.2007.03.007 [DOI] [PubMed] [Google Scholar]
  • 9.Higa DH, Marks G, Crepaz N, Liau A, Lyles CM. Interventions to Improve Retention in HIV Primary Care: A Systematic Review of U.S. Studies. Current HIV/AIDS Reports. 2012;9(4):313–25. 10.1007/s11904-012-0136-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Bradford J, Coleman S, Cunningham W. HIV System Navigation: An Emerging Model to Improve HIV Care Access. 2007;21(s1):S-49–S-58. 10.1089/apc.2007.9987 . [DOI] [PubMed] [Google Scholar]
  • 11.Enriquez M, Cheng A-L, McKinsey D, Farnan R, Ortego G, Hayes D, et al. Peers Keep It Real: Re-engaging Adults in HIV Care. Journal of the International Association of Providers of AIDS Care (JIAPAC). 2019;18:2325958219838858. 10.1177/2325958219838858 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Gardner LI, Marks G, Craw JA, Wilson TE, Drainoni M-L, Moore RD, et al. A low-effort, clinic-wide intervention improves attendance for HIV primary care. Clin Infect Dis. 2012;55(8):1124–34. Epub 2012/07/24. 10.1093/cid/cis623 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Higa DH, Crepaz N, Mullins MM, The Prevention Research Synthesis P. Identifying Best Practices for Increasing Linkage to, Retention, and Re-engagement in HIV Medical Care: Findings from a Systematic Review, 1996–2014. AIDS Behav. 2016;20(5):951–66. 10.1007/s10461-015-1204-x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Liau A, Crepaz N, Lyles CM, Higa DH, Mullins MM, DeLuca J, et al. Interventions to promote linkage to and utilization of HIV medical care among HIV-diagnosed persons: a qualitative systematic review, 1996–2011. AIDS Behav. 2013;17(6):1941–62. 10.1007/s10461-013-0435-y . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Okeke NL, Ostermann J, Thielman NM. Enhancing Linkage and Retention in HIV Care: a Review of Interventions for Highly Resourced and Resource-Poor Settings. Current HIV/AIDS Reports. 2014;11(4):376–92. 10.1007/s11904-014-0233-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Maulsby C, Enobun B, Batey DS, Jain KM, Access to Care Intervention T, Riordan M, et al. A Mixed-Methods Exploration of the Needs of People Living with HIV (PLWH) Enrolled in Access to Care, a National HIV Linkage, Retention and Re-Engagement in Medical Care Program. AIDS Behav. 2018;22(3):819–28. 10.1007/s10461-017-1809-3 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Duncombe C, Rosenblum S, Hellmann N, Holmes C, Wilkinson L, Biot M, et al. Reframing HIV care: putting people at the centre of antiretroviral delivery. Trop Med Int Health. 2015;20(4):430–47. Epub 2015/02/16. 10.1111/tmi.12460 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Centers for Disease Control and Prevention. CDC HIV Prevention Progress Report, 2019. 2019.
  • 19.Georgia Department of Public Health. Georgia Integrated HIV Prevention & Care Plan 2017–2021. 2016.
  • 20.Yu SWY, Hill C, Ricks ML, Bennet J, Oriol NE. The scope and impact of mobile health clinics in the United States: a literature review. Int J Equity Health. 2017;16(1):178-. 10.1186/s12939-017-0671-2 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Mobile Health Map: Harvard Medical School; 2019 [cited 2019]. https://www.mobilehealthmap.org/.
  • 22.Ellen JM, Bonu S, Arruda JS, Ward MA, Vogel R. Comparison of clients of a mobile health van and a traditional STD clinic. J Acquir Immune Defic Syndr. 2003;32(4):388–93. Epub 2003/03/18. 10.1097/00126334-200304010-00007 . [DOI] [PubMed] [Google Scholar]
  • 23.Liebman J, Pat Lamberti M, Altice F. Effectiveness of a Mobile Medical Van in Providing Screening Services for STDs and HIV. Public Health Nursing. 2002;19(5):345–53. 10.1046/j.1525-1446.2002.19504.x [DOI] [PubMed] [Google Scholar]
  • 24.Spielberg F, Kurth A, Reidy W, McKnight T, Dikobe W, Wilson C. Iterative evaluation in a mobile counseling and testing program to reach people of color at risk for HIV—new strategies improve program acceptability, effectiveness, and evaluation capabilities. AIDS Educ Prev. 2011;23(3 Suppl):110–6. Epub 2011/06/28. 10.1521/aeap.2011.23.3_supp.110 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Edgerley LP, El-Sayed YY, Druzin ML, Kiernan M, Daniels KI. Use of a Community Mobile Health Van to Increase Early Access to Prenatal Care. Maternal and Child Health Journal. 2007;11(3):235–9. 10.1007/s10995-006-0174-z [DOI] [PubMed] [Google Scholar]
  • 26.Altice FL, Bruce RD, Walton MR, Buitrago MI. Adherence to hepatitis B virus vaccination at syringe exchange sites. J Urban Health. 2005;82(1):151–61. Epub 2005/03/05. 10.1093/jurban/jti016 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Clark HA, Bowles KE, Song B, Heffelfinger JD. Implementation of rapid HIV testing programs in community and outreach settings: perspectives from staff at eight community-based organizations in seven U.S. cities. Public Health Rep. 2008;123 Suppl 3(Suppl 3):86–93. 10.1177/00333549081230S311 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Moon TD, Jequicene T, Blevins M, José E, Lankford JR, Wester CW, et al. Mobile clinics for antiretroviral therapy in rural Mozambique. Bull World Health Organ. 2014;92(9):680–4. Epub 2014/06/19. 10.2471/BLT.13.129478 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Pasipamire L, Nesbitt RC, Ndlovu S, Sibanda G, Mamba S, Lukhele N, et al. Retention on ART and predictors of disengagement from care in several alternative community-centred ART refill models in rural Swaziland. Journal of the International AIDS Society. 2018;21(9):e25183–e. 10.1002/jia2.25183 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Gorman SE, Martinez JM, Olson J. An assessment of HIV treatment outcomes among utilizers of semi-mobile clinics in rural Kenya. AIDS Care. 2015;27(5):665–8. 10.1080/09540121.2014.986053 [DOI] [PubMed] [Google Scholar]
  • 31.Barnabas R. Delivery Optimization for Antiretroviral Therapy (The DO ART Study) (DO ART) 2018. https://clinicaltrials.gov/ct2/show/NCT02929992?term=Delivery+Optimization+for+Antiretroviral+Therapy&rank=1.
  • 32.Altice FL, Springer S, Buitrago M, Hunt DP, Friedland GH. Pilot study to enhance HIV care using needle exchange-based health services for out-of-treatment injecting drug users. J Urban Health. 2003;80(3):416–27. Epub 2003/08/22. 10.1093/jurban/jtg053 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Paris N, Porter-O’Grady T. Health on Wheels. Health Progress. 1994. [PubMed] [Google Scholar]
  • 34.Edwards AL. Street Medicine: A Program Evaluation: Georgia State University; 2017.
  • 35.Mercy Care. Services and Programs—Outreach 2019 [cited 2019]. https://mercyatlanta.org/services/.
  • 36.Kahn RH, Moseley Kera E., Thilges John N., Johnson Gwendolyn, Farley Thomas A. Community-Based Screening and Treatment for STDs: Results from a Mobile Clinic Initiative. Sex Transm Dis. 2003;30(8). 10.1097/01.OLQ.0000083892.66236.7A [DOI] [PubMed] [Google Scholar]
  • 37.Post P. Mobile Health Care for Homeless People: Using Vehicles to Extend Care. Nashville: National Health Care for the Homeless Council, Inc., 2007. [Google Scholar]
  • 38.Kvale S. Doing Interviews. Thousand Oaks, CA: SAGE Publications; 2008. 2008. [Google Scholar]
  • 39.Altice FL, Mezger JA, Hodges J, Bruce RD, Marinovich A, Walton M, et al. Developing a Directly Administered Antiretroviral Therapy Intervention for HIV-Infected Drug Users: Implications for Program Replication. Clinical Infectious Diseases. 2004;38(Supplement_5):S376–S87. 10.1086/421400 [DOI] [PubMed] [Google Scholar]
  • 40.Schwitters A, Lederer P, Zilversmit L, Gudo PS, Ramiro I, Cumba L, et al. Barriers to health care in rural Mozambique: a rapid ethnographic assessment of planned mobile health clinics for ART. Glob Health Sci Pract. 2015;3(1):109–16. 10.9745/GHSP-D-14-00145 . [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision Letter 0

Bronwyn Myers

23 Nov 2020

PONE-D-20-30821

Barriers and Facilitators to use of a mobile HIV care model to re-engage and retain out-of-care people living with HIV in Atlanta, Georgia

PLOS ONE

Dear Dr. Kalokhe

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Jan 07 2021 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

We look forward to receiving your revised manuscript.

Kind regards,

Bronwyn Myers

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2.  Please include additional information regarding the survey or questionnaire used in the study and ensure that you have provided sufficient details that others could replicate the analyses. For instance, if you developed a questionnaire as part of this study and it is not under a copyright more restrictive than CC-BY, please include a copy, in both the original language and English, as Supporting Information, or include a citation if it has been published previously.

3. In the Methods, please discuss whether and how the questionnaire was validated and/or pre-tested. If these did not occur, please provide the rationale for not doing so.

4. We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For information on unacceptable data access restrictions, please see http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions.

In your revised cover letter, please address the following prompts:

a) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially identifying or sensitive patient information) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent.

b) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. Please see http://www.bmj.com/content/340/bmj.c181.long for guidelines on how to de-identify and prepare clinical data for publication. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories.

We will update your Data Availability statement on your behalf to reflect the information you provide.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: N/A

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: This article examined barriers and facilitators to the use of mobile HIV care clinics to re-engage people living with HIV who are out of care. This study fills an important gap by exploring the feasibility of mobile health clinics in the United States. The study strengths include the variety of stakeholders interviewed and engagement of a community advisory board.

There are several areas that need to be strengthened. The methods need to be expanded to describe the sampling and analysis process used. The results need to more clearly indicate which barriers are of most concern to each stakeholder group. Finally, the discussion needs to provide a more a nuanced analysis of the main findings. I offer the following suggestions:

Introduction

Well written!

Methods

• Line 67: Describe the sampling strategy used. Was there a target # for each stakeholder group?

• Line 69: Describe the composition of the Community Advisory Board

• Line 78: Was the same interview guide used for each stakeholder group?

• Line 89 Provide more description of the analysis process. For the line, “...additional inductive codes added based on initial interviews” did coding commence while interviews were being conducted, or does this mean that codes were developed after reviewing a few initial transcripts? Describe the initial process of establishing consistency among coders and the interpretation process. It would be helpful to know how transcripts from each stakeholder group compared.

Results

• The results represent a variety of stakeholder groups which express different barriers and facilitators. For each section, specify which specific stakeholder group is having the concern (e.g. is it only healthcare providers concerned about staffing and time limitations?) to help readers discern which are the most widely held barriers and facilitators for each group.

• Remove Table 2 as it does not add to the results.

• There are currently no quotes representing mobile health clinic staff. Integrate some quotes from this group as they may have the most direct experience with this care delivery model.

• Overall, the results section is quite long. Cut back on the length of some of the longer quotes (i.e. line 318, line 269). Additionally, similar sections should be combined. The sections “potentially falling out of other medical care” and “Decreasing patients’ responsibility and self-efficacy in their care” are similar, as are the sections “community acceptance and safety” and “safety concerns.” Combined into one paragraph.

Discussion

• Line 364: the discussion of all the main findings are condensed in one paragraph. This paragraph should be broken down to add more nuance to findings. For example, the point about increasing security personnel may be in direct contrast to patient concerns about emotional and physical safety. The suggestion in the results that police be brought in may heighten concerns as some PLWH who are out of care may engage in criminalized behaviors. Additionally, there is no discussion about how trust can be built between MHCs and patients.

• Line 389: Add to the limitations that “of the 41 interviews, only 5 were of PLWH.” It is a major limitation that they are underrepresented among study participants.

• Line 393: In the conclusion, include a line or two synthesizing main barriers and facilitators.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2021 Mar 11;16(3):e0247328. doi: 10.1371/journal.pone.0247328.r002

Author response to Decision Letter 0


22 Dec 2020

Response to Reviewer

Introduction

Well written!

Thank you.

Methods

Line 67: Describe the sampling strategy used. Was there a target # for each stakeholder group?

The study utilized purposive sampling to explore a diversity of stakeholder group perspectives. Our target goal was to achieve 10 clinic staff and providers, 10 people living with HIV (PLWH; 5 PLWH who were out of care, and 5 PLWH who were Consumer Advisory Board members), 10 organizations providing community-based HIV clinical and support services for PLWH (including other mobile clinics, AIDS service organizations, etc.), and 10 institutional and city-based regulatory, billing, and, medico-legal compliance experts. Sample size targets were based on Kvale’s estimate that 15+/-5 individuals from a group is sufficient to reach theoretical saturation.1Although we did not reach the target for the compliance/regulatory officials category, we concluded enrollment once we as a team concluded we had reached theoretical saturation. A description of the sampling strategy has been added to the Methods section on lines 69-72.

Line 69: Describe the composition of the Community Advisory Board

The Consumer Advisory Board (CAB) was made up of approximately 10 PLWH who receive HIV care at the study clinic. They were nominated to the CAB based on their interest in HIV advocacy and in enhancing the services provided within the clinic’s Ryan White Program. They represent various racial/ethnic, gender and sexual minority groups, and many endorse having had a period in their lives where they were out-of-care or struggled with their HIV diagnosis and appointment adherence and are able to describe strategies they used to overcome the challenges. A description of the composition of the CAB has been added to the Methods section on lines 80-85.

Line 78: Was the same interview guide used for each stakeholder group?

Different interview guides were used for each stakeholder group. While each guide asked open-ended questions about barriers, facilitators, and strategies for using a mobile HIV clinic (MHC) to deliver care, probes that followed were tailored to the stakeholder group. For example, in follow-up to an open-ended question about challenges with mobile HIV care delivery, providers and staff were probed about time, support, and technology challenges in addition to concerns around safety, privacy and confidentiality, while patients were probed about perceived challenges with MHC access and location (in addition to safety, privacy, and confidentiality). Clarification on the differences between interview guides has been added to the Methods section on lines 95-101.

Line 89 Provide more description of the analysis process. For the line, “...additional inductive codes added based on initial interviews” did coding commence while interviews were being conducted, or does this mean that codes were developed after reviewing a few initial transcripts? Describe the initial process of establishing consistency among coders and the interpretation process. It would be helpful to know how transcripts from each stakeholder group compared.

We commenced coding alongside conducting the interviews, so that inductive codes arising from earlier transcripts could be probed further in subsequent interviews. The codebook was developed after the first three interviews and included deductive codes derived directly from the interview guide and inductive codes that emerged directly from the interviews. To establish consistency of coding and interpretation, definitions and examples of each code were included in the codebook and presented and discussed at research team meetings, all transcripts were coded by two research team members, and discrepancies in coding were discussed until consensus was reached. When consensus could not easily be reached between the two coders regarding interpretation of a transcript and appropriate code, the code and text in question was presented at the weekly team meeting for further discussion until consensus was achieved. See below response regarding how transcripts from each stakeholder group compared. Additional description on the analysis process has been added to the Methods section on lines 107-117.

Results

The results represent a variety of stakeholder groups which express different barriers and facilitators. For each section, specify which specific stakeholder group is having the concern (e.g. is it only healthcare providers concerned about staffing and time limitations?) to help readers discern which are the most widely held barriers and facilitators for each group.

For each section within the results, stakeholder groups that primarily brought up each barrier are described.

Remove Table 2 as it does not add to the results.

Table 2 is now removed.

There are currently no quotes representing mobile health clinic staff. Integrate some quotes from this group as they may have the most direct experience with this care delivery model.

Quotes representing mobile health clinic staff were integrated throughout the results section, within barriers: “confidentiality and stigma concerns” (line 140), “lack of physical and emotional comfort” (line 180), and “Adequate awareness of the MHC among the target population” (line 352).

Overall, the results section is quite long. Cut back on the length of some of the longer quotes (i.e. line 318, line 269). Additionally, similar sections should be combined. The sections “potentially falling out of other medical care” and “Decreasing patients’ responsibility and self-efficacy in their care” are similar, as are the sections “community acceptance and safety” and “safety concerns.” Combined into one paragraph.

Lines 318 and 269 were shortened. The header “Potentially falling out of other medical care” was removed and the text under this heading was abridged and moved to the header “Decreasing patients’ responsibility and self-efficacy in their care.” We chose to not combine the sections “safety concerns” and “community acceptance and safety" as the themes described under each section are different. The former describes clinic-level safety concerns (i.e. theft of supplies) and informs clinic-level strategies for enhancing safety (i.e. security personnel, installation of panic buttons and cameras, safety training of staff), whereas the latter describes environment-level concerns (including safety concerns) that arise from inadequate engagement of the community (i.e. the neighborhoods where the MHC would be parked) in the process of MHC design and implementation and suggests environment-level strategies to address this concern (i.e. partnering with community-based organizations and local government).

Discussion

Line 364: the discussion of all the main findings are condensed in one paragraph. This paragraph should be broken down to add more nuance to findings. For example, the point about increasing security personnel may be in direct contrast to patient concerns about emotional and physical safety. The suggestion in the results that police be brought in may heighten concerns as some PLWH who are out of care may engage in criminalized behaviors. Additionally, there is no discussion about how trust can be built between MHCs and patients.

We fully agree with the reviewer and have expanded this paragraph for a more nuanced discussion of the implication of study findings in informing MHC design. Additions are on lines 436-438, 442-447, 450-455.

Line 389: Add to the limitations that “of the 41 interviews, only 5 were of PLWH.” It is a major limitation that they are underrepresented among study participants.

11 of the interviews were PLWH, including 5 who were out of care and 6 from the CAB. Language was added on lines 69-71 of the Methods section describing this sampling strategy. The team unanimously felt that we reached theoretical saturation with the 5 interviews with PLWH who were out of care and 6 PLWH who were on the CAB. Additionally, the qualitative findings presented in this manuscript are part of a mixed-methods study, which includes surveys (not published here) with 50 PLWH who are out-of-care that examine their relative preference for mobile HIV care versus several other community-based models of HIV care delivery and gauge their specific preferences for MHC implementation.

Line 393: In the conclusion, include a line or two synthesizing main barriers and facilitators.

The following line has now been added, “Key factors influencing use of the MHC include the extent to which patients feel physically and emotionally safe (including their perceptions of the potential of the MHC to maintain confidentiality and privacy), the extent to which the MHC provides comprehensive integrated HIV and non-HIV services, the level of community acceptance of the MHC in their locality, cost-effectiveness of the MHC, and the development and use of effective strategies to reach and engage out-of-care PLWH. Next steps include development of the MHC model to address these factors with the continued participation of the various stakeholders, followed by MHC piloting” (lines 474-481).

Additional References

1. Kvale S. Doing Interviews. Thousand Oaks, CA: SAGE Publications; 2008.

Attachment

Submitted filename: PLOS ONE_response_submitted12.21.20.docx

Decision Letter 1

Bronwyn Myers

5 Feb 2021

Barriers and Facilitators to use of a mobile HIV care model to re-engage and retain out-of-care people living with HIV in Atlanta, Georgia

PONE-D-20-30821R1

Dear Dr. Kalokhe,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Bronwyn Myers

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: (No Response)

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: (No Response)

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: (No Response)

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: (No Response)

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: (No Response)

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Acceptance letter

Bronwyn Myers

18 Feb 2021

PONE-D-20-30821R1

Barriers and Facilitators to use of a mobile HIV care model to re-engage and retain out-of-care people living with HIV in Atlanta, Georgia

Dear Dr. Kalokhe:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Bronwyn Myers

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    Attachment

    Submitted filename: PLOS ONE_response_submitted12.21.20.docx

    Data Availability Statement

    The data underlying this study cannot be shared publicly because of confidentiality concerns. Data are available from the Emory IRB (irb@emory.edu) or via the corresponding author.


    Articles from PLoS ONE are provided here courtesy of PLOS

    RESOURCES